We are live on ! Find out more
RNXT icon

RenovoRx
RNXT

14 hedge funds and large institutions have $473K invested in RenovoRx in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more funds holding

Funds holding: 9 → 14 (+5)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.99% more ownership

Funds ownership: 2.41% → 3.4% (+0.99%)

14% less capital invested

Capital invested by funds: $552K → $473K (-$78.7K)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$88.6K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$34.6K
3
State Street
State Street
Massachusetts
+$33.9K
4
BlackRock
BlackRock
New York
+$27.6K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$24.6K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$11.7K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.64K

RNXT Hedge Fund Activity: Q3 2023 in Review

14 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in RenovoRx (RNXT) for Q3 2023, worth a combined $473K — down 14% from $552K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new RNXT positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Charles Schwab, opening a new position worth an estimated $88.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $11.7K.

  • 14 institutional investors held RenovoRx (RNXT) as of Q3 2023, up from 9 in Q2 2023.
  • Funds reported $473K of RenovoRx stock for Q3 2023, down 14% quarter-over-quarter.
  • 5 funds opened new RenovoRx positions in Q3 2023 and 0 closed out, a net change of +5 holders.
  • The largest RenovoRx buyer in Q3 2023 was Charles Schwab, an estimated $88.6K added.
  • The largest RenovoRx seller in Q3 2023 was Tower Research Capital (TRC), an estimated $11.7K sold.

Based on aggregated 13F filings for Q3 2023.